The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electroca
about
Ticagrelor therapy and atrioventricular block: Do we need to worry?Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registryTicagrelor-Associated Conduction Disorder: A Case Report and Review of the Literature.Southern Saskatchewan Ticagrelor Registry experience.Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO studyTicagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.Critical appraisal of ticagrelor in the management of acute coronary syndromeAdvances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelorCase Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes.Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.P2Y12 platelet inhibition in clinical practice.A comprehensive comparative review of adenosine diphosphate receptor antagonists.InforMatrix: ADP antagonists in acute coronary syndromes.Review of ticagrelor in the management of acute coronary syndromes.Safety profile and bleeding risk of ticagrelor compared with clopidogrel.Prehospital treatment of ST-segment elevated myocardial infarction patients.Ticagrelor: positive, negative and misunderstood properties as a new antiplatelet agent.Antiplatelet therapy: new pharmacological agents and changing paradigms.Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.Ticagrelor for acute coronary syndromes.Updates in antiplatelet agents used in cardiovascular diseases.Ticagrelor: a review of its use in adults with acute coronary syndromes.P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal useAntithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis.Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.Ticagrelor and bradycardia: a nested case-control study.Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study.The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease.Is ticagrelor safe in intensive care unit patients? Focus on bradycardic events.Ticagrelor - toward more efficient platelet inhibition and beyond.P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome.
P2860
Q33695952-60209D77-E923-480F-BC1C-A8F217BC071BQ33817357-97A92C14-4A74-4047-A303-CF31A094F781Q33893920-4571720B-5AA5-4953-B631-7FADAEE65A99Q34387201-0873475C-DC2F-40A3-8A90-BD33B97C6652Q34456208-14132F31-7049-4434-9802-0A0CE1003A10Q34805121-79B1A17F-F721-4193-9FE7-E3CC1C0321FFQ35660767-13A3A213-8495-4D2E-9E61-8E228C7F43CAQ36807413-0DB80A02-5EBE-417F-A940-29FED3AEE372Q37403998-033FF8C8-8C85-4F83-AAAA-AED02C9CED0CQ37959155-D406CE12-8789-48B0-8703-D3FFF2399B99Q37969927-B1B02A1B-A7CB-4525-82FF-12BDAB596C56Q37973114-015B4782-E315-48B1-8941-0EC03735D19EQ37973397-E75108B1-F6CB-4269-82D9-B13A8837C101Q38038255-C2B9E0AB-F63D-466E-BB4E-134E897590B8Q38040816-F80A86C7-5D3C-4005-B1F7-EF455CEB95BCQ38086844-C1088D1F-C591-4BA7-8E2F-D914DFFC9A9AQ38099380-A39F2951-DA8D-4E1C-B44E-EC4F30AFBEB3Q38117743-B2F4DA53-596C-467C-8EC6-22D034C3423BQ38128171-C3E6FC41-032A-4B87-BFE0-D4130E9EC403Q38154611-BBF3C602-2CA1-4755-9EBF-D6A58189762BQ38161394-FAB23620-DB71-45D7-A70B-626CED89CAFCQ38352069-AF4963B9-31E0-4D38-88A4-ACAB99925E39Q38542096-4886C4E3-9EEF-4758-83EE-1C469D8C6E9FQ38545163-408FEDAA-113B-461E-A4FA-8C8A24EFD4A5Q38974884-E0EB927F-24B6-4551-8856-C2B532DA371FQ40453126-BDA1FF01-6FAB-49F3-A5D3-3F6417F4FDF1Q41060485-9BDD84F2-5B28-48CE-814C-294C4E84F2EAQ41352369-63F9995C-05E6-46D2-B9C6-FCB1AF1DF3E4Q41456276-113492CB-BD56-4D6D-8BA9-D7DFCC445461Q48212069-1EAE3A78-E881-405B-8467-B693B05C4D34Q49337303-E8A1B28F-1978-40D2-AF6B-AE1459C8519DQ51539033-DCEEACF8-2854-4AFE-9BF9-428F0DB087BC
P2860
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electroca
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The incidence of bradyarrhythm ...... ts of the continuous electroca
@ast
The incidence of bradyarrhythm ...... ts of the continuous electroca
@en
type
label
The incidence of bradyarrhythm ...... ts of the continuous electroca
@ast
The incidence of bradyarrhythm ...... ts of the continuous electroca
@en
prefLabel
The incidence of bradyarrhythm ...... ts of the continuous electroca
@ast
The incidence of bradyarrhythm ...... ts of the continuous electroca
@en
P2093
P50
P921
P1476
The incidence of bradyarrhythm ...... ts of the continuous electroca
@en
P2093
Benjamin M Scirica
Christopher P Cannon
Dimitar Raev
Eric L Michelson
Hugo Katus
Jindrich Spinar
PLATO Investigators
Ph Gabriel Steg
Steen Husted
P304
P356
10.1016/J.JACC.2010.11.056
P407
P577
2011-05-01T00:00:00Z